Avertix Medical
First and only FDA-Approved Implantable Cardiac Surveillance System | A New Day Dawns for Heart Attack Survivors and ACD
First and only FDA-Approved Implantable Cardiac Surveillance System | A New Day Dawns for Heart Attack Survivors and ACD
Avertix Medical is a pioneering company in the Health Care and Medical Devices industries. Their FDA-approved Guardian System offers an innovative approach to managing Advanced Cardiovascular Disease. The system is designed to alert patients to seek medical attention for Acute Coronary Syndrome, including silent heart attacks, addressing the issue of delayed treatment contributing to high mortality and morbidity rates. With less than 20% of patients presenting to the emergency room actually experiencing a true positive ACS event, and more than one-third of heart attacks having atypical or no symptoms, Avertix’s Guardian System aims to fill a crucial gap in patient care. Founded in 2001, Avertix recently secured a significant $13.48M in Debt Financing investment on 13 November 2023, showcasing investor confidence in the company's mission to advance patient care standards.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $13.48M | - | 13 Nov 2023 |
No recent news or press coverage available for Avertix Medical.
We care about your data, and we'd love to use cookies make your experience better.
